Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CAI:NIPH's EV-to-EBITDA is ranked worse than 84.31% of 733
companies
in the Drug Manufacturers industry
Industry Median: 13.06
vs CAI:NIPH: 37.78
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's PE Ratio (TTM) for today is calculated as:
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's share price for today is E£372.30.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£5.039.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EV-to-EBITDA Chart
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Annual Data
Trend
Jun24
Jun25
EV-to-EBITDA
1.89
9.83
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Quarterly Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EV-to-EBITDA vs Drug Manufacturers Industry
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Enterprise Value is E£19,902 Mil.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£527 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a EV-to-EBITDA of 37.78 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile. This is 171% above median its historical median of 13.92. Over the past decade, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EV-to-EBITDA has ranged from 9.79 to 41.36. According to the industry distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #618 out of 733 companies in the Drug Manufacturers industry, placing it in the top 84.3%.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EV-to-EBITDA too high?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current EV-to-EBITDA of 37.78 is 171% above median its 10-year median of 13.92. Over the past 10 years, this metric has ranged from a low of 9.79 to a high of 41.36. The Drug Manufacturers industry median EV-to-EBITDA is 13.06. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's value of 37.78 is 189.3% above this industry median. Based on the distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #618 out of 733 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #618 out of 733 companies for EV-to-EBITDA. This places El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile in the lower half of its industry. The industry median EV-to-EBITDA is 13.06. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's value of 37.78 is 189.3% above this benchmark. Historically, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's own EV-to-EBITDA has ranged from 9.79 to 41.36 over the past decade. While the company's 10-year median is 13.92 vs. the industry median of 13.06, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.06, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current EV-to-EBITDA of 37.78 is 189.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current EV-to-EBITDA is 37.78, which is 171% above median its own 10-year median of 13.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile stock overvalued right now?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a current EV-to-EBITDA of 37.78. The current EV-to-EBITDA is 37.78, which is 171% above median its 10-year median of 13.92 and 189.3% above the Drug Manufacturers industry median of 13.06. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH), the current EV-to-EBITDA is 37.78 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile manufactures and markets pharmaceuticals, medicinal materials, chemical products and surgical threads and medical solutions.
28GF Score
Get the complete analysis for CAI:NIPH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:NIPH has been successfully added to your 
